Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

被引：2
|
作者：
Eliason, Laurie
Correll, Julia
Martin, Mona
Cardellino, Anna
Opalinska, Joanna
Piontek, Trisha
Gorsh, Boris
Sapra, Sandhya
Popat, Rakesh
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139395
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2
    Kortuem, M.
    Trudel, S.
    Cohen, A. D.
    Richardson, P. G.
    Lonial, S.
    Opalinska, J. B.
    Gupta, I
    Byrne, J.
    Zhi, E.
    Baron, J.
    Morgan, L.
    Voorhees, P. M.
    Popat, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 97 - 98
  • [22] DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Rifkin, Robert M.
    Boyd, Kevin
    Grosicki, Sebastian
    Kim, Kihyun
    Di Raimondo, Francesco
    Dimopoulos, Meletios A.
    Weisel, Katja
    Arnulf, Bertrand
    Hajek, Roman
    Hungria, Vania T. M.
    Spencer, Andrew
    Davis, Randy
    Riccio, Antonio
    Kim, Chanbin
    Wilkes, Jodie
    Rutledge, Ruth
    Talekar, Mala
    Kremer, Brandon E.
    Gupta, Ira
    Mateos, Maria-Victoria
    BLOOD, 2020, 136
  • [23] DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
    Nooka, Ajay K.
    Stockerl-Goldstein, Keith
    Quach, Hang
    Forbes, Adam
    Mateos, Maria-Victoria
    Khot, Amit
    Tan, Alan
    Abonour, Rafat
    Chopra, Bikramjit
    Rogers, Rachel
    Ferron-Brady, Geraldine
    Davidge, Jacqueline
    Frey, Steve
    Yeakey, Anne
    Talekar, Mala
    Luptakova, Katarina
    Gupta, Ira
    Popat, Rakesh
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
    Lonial, Sagar
    Lee, Hans C.
    Badros, Ashraf
    Trudel, Suzanne
    Nooka, Ajay K.
    Chari, Ajai
    Abdallah, Al-Ola
    Callander, Natalie
    Lendvai, Nikoletta
    Sborov, Douglas
    Suvannasankha, Attaya
    Weisel, Katja
    Karlin, Lionel
    Libby, Edward
    Arnulf, Bertrand
    Facon, Thierry
    Hulin, Cyrille
    Kortum, K. Martin
    Rodriguez-Otero, Paula
    Usmani, Saad Z.
    Hari, Parameswaran
    Baz, Rachid
    Hang Quach
    Moreau, Philippe
    Voorhees, Peter M.
    Gupta, Ira
    Hoos, Axel
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Lewis, Eric
    Jewell, Roxanne C.
    Dettman, Elisha J.
    Popat, Rakesh
    Esposti, Simona Degli
    Opalinska, Joanna
    Richardson, Paul
    Cohen, Adam D.
    LANCET ONCOLOGY, 2020, 21 (02): : 207 - 221
  • [25] Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
    Richardson, Paul G.
    Lee, Hans C.
    Abdallah, Al-Ola
    Cohen, Adam D.
    Kapoor, Prashant
    Voorhees, Peter M.
    Hoos, Axel
    Wang, Karrie
    Baron, January
    Piontek, Trisha
    Byrne, Julie
    Richmond, Scott
    Jewell, Roxanne C.
    Opalinska, Joanna
    Gupta, Ira
    Lonial, Sagar
    BLOOD CANCER JOURNAL, 2020, 10 (10)
  • [26] Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
    Sheikh, Semira
    Lebel, Eyal
    Trudel, Suzanne
    FUTURE ONCOLOGY, 2020, 16 (34) : 2783 - 2798
  • [27] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) cytogenetics
    Besemer, B.
    Cohen, A. D.
    Trudel, S.
    Lonial, S.
    Libby, E.
    Lee, H. C.
    Facon, T.
    Nooka, A. K.
    Callander, N.
    Chari, A.
    Gupta, I
    Paul, S.
    Opalinska, J.
    Richardson, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 98 - 98
  • [28] DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
    Thibaud Prawitz
    Rakesh Popat
    Attaya Suvannasankha
    Grammati Sarri
    Rachel Hughes
    Feng Wang
    Cosmina Hogea
    Shannon Allen Ferrante
    Boris Gorsh
    Jenny Willson
    Venediktos Kapetanakis
    Advances in Therapy, 2021, 38 : 5501 - 5518
  • [29] Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.
    Suvannasankha, Attaya
    Bahlis, Nizar J.
    Trudel, Suzanne
    Weisel, Katja
    Koenecke, Christian
    Rocafiguera, Albert Oriol
    Voorhees, Peter M.
    Alonso, Aranzazu Alonso
    Callander, Natalie Scott
    Mateos, Maria-Victoria
    Reddy, Nishitha
    Hakim, Shawn
    Patel, Nashita
    Williams, Danae
    Jewell, Roxanne C.
    Zhou, Xiangdong
    Gupta, Ira V.
    Nooka, Ajay K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Lowther, Daniel E.
    Houseman, E. Andres
    Han, Gang
    Kleanthous, Eleni
    Knoblock, Dawson
    Zhou, Xiangdong
    Banerjee, Shreyan
    Patel, Sagar
    Figueroa, David
    BLOOD, 2022, 140
12345